{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T05:35:31Z","timestamp":1791264931472,"version":"4.1.0"},"reference-count":39,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T00:00:00Z","timestamp":1767312000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Alpha-fetoprotein-producing gastric cancer (AFPGC) is a rare, aggressive subtype with poor prognosis. We report a metastatic AFPGC case showing spatiotemporal human epidermal growth factor receptor 2 (HER2) heterogeneity. Following progression on first-line FLOT chemotherapy, the 65-year-old male received second-line apatinib plus programmed death-1 (PD-1) inhibitor. At progression (27 months), a lymph node biopsy revealed HER2 conversion from 1+ to 3 +. Third-line anti-HER2 antibody-drug conjugate (ADC) DP303c rapidly achieved partial response with normalized AFP. Despite treatment discontinuation due to neurotoxicity after 5 cycles, response persisted. Overall survival reached 79 months. This case highlights: 1) efficacy of anti-angiogenic and immunotherapy in AFPGC; 2) necessity of re-biopsy for detecting HER2 heterogeneity; and 3) potent activity of ADCs against HER2-converted metastases, enabling remarkable survival through sequential precision therapy.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1696069","type":"journal-article","created":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T06:28:33Z","timestamp":1767335313000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Case report: Spatiotemporal HER2 heterogeneity in AFP-producing gastric cancer: navigating long-term survival with molecularly-guided therapy in a refractory case"],"prefix":"10.3389","volume":"16","author":[{"given":"Yanwen","family":"Diao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haobo","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingdong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,2]]},"reference":[{"key":"B1","article-title":"Serum alpha-fetoprotein in patients with neoplasms of the gastrointestinal tract","volume":"35","author":"McIntire","year":"1975","journal-title":"Cancer Res"},{"key":"B2","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1111\/pin.12390","article-title":"New guidelines for HER2 pathological diagnostics in gastric cancer","volume":"66","author":"Wada","year":"2016","journal-title":"Pathol Int"},{"key":"B3","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s13578-025-01424-8","article-title":"Alpha fetoprotein (AFP)-producing gastric cancer: clinicopathological features and treatment strategies","volume":"15","author":"Luo","year":"2025","journal-title":"Cell bioscience"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v19.i36.6055","article-title":"Liver metastasis is the only independent prognostic factor in AFP-producing gastric cancer","volume":"19","author":"Hirajima","year":"2013","journal-title":"World J gastroenterol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2020.101004","article-title":"Efficacy and safety of apatinib for the treatment of AFP-producing gastric cancer","volume":"14","author":"Li","year":"2021","journal-title":"Trans Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3747\/co.21.1768","article-title":"Clinical manifestations in patients with alpha-fetoprotein-producing gastric cancer","volume":"21","author":"Lin","year":"2014","journal-title":"Curr Oncol (Toronto Ont)"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.901061","article-title":"Elevated serum alpha-fetoprotein is a significant prognostic factor for patients with gastric cancer: results based on a large-scale retrospective study","volume":"12","author":"Zhan","year":"2022","journal-title":"Front Oncol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.humpath.2021.02.003","article-title":"Integrated clinicopathological and immunohistochemical analysis of gastric adenocarcinoma with hepatoid differentiation: an exploration of histogenesis, molecular characteristics, and prognostic markers","volume":"115","author":"He","year":"2021","journal-title":"Hum pathol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.humpath.2018.04.022","article-title":"Next-generation sequencing analysis for gastric adenocarcinoma with enteroblastic differentiation: emphasis on the relationship with hepatoid adenocarcinoma","volume":"78","author":"Akazawa","year":"2018","journal-title":"Hum pathol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-002-1099-y","article-title":"Evaluation of VEGF and VEGF-C expression in gastric cancer cells producing alpha-fetoprotein","volume":"38","author":"Kamei","year":"2003","journal-title":"J gastroenterol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1097\/md.0000000000004610","article-title":"A case report of targeted therapy with apatinib in a patient with advanced gastric cancer and high serum level of alpha-fetoprotein","volume":"95","author":"Zhu","year":"2016","journal-title":"Medicine"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.2147\/cmar.s276969","article-title":"Effect of immune checkpoint inhibitors plus chemotherapy on advanced gastric cancer patients with elevated serum AFP or hepatoid adenocarcinoma","volume":"12","author":"Li","year":"2020","journal-title":"Cancer Manage Res"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-021-01976-2","article-title":"Genomic and transcriptomic profiling of hepatoid adenocarcinoma of the stomach","volume":"40","author":"Liu","year":"2021","journal-title":"Oncogene"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1487610","article-title":"Leveraging the synergy between anti-angiogenic therapy and immune checkpoint inhibitors to treat digestive system cancers","volume":"15","author":"Xu","year":"2024","journal-title":"Front Immunol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.neo.2024.101077","article-title":"Sequential treatment of anti-PD-L1 therapy prior to anti-VEGFR2 therapy contributes to more significant clinical benefits in non-small cell lung cancer","volume":"59","author":"Lin","year":"2025","journal-title":"Neoplasia (New York NY)"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-025-01211-z","article-title":"Linking tumour angiogenesis and tumour immunity","volume":"14","author":"Kabir","year":"2025","journal-title":"Nat Rev Immunol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2023.110413","article-title":"All-trans-retinoic acid inhibits hepatocellular carcinoma progression by targeting myeloid-derived suppressor cells and inhibiting angiogenesis","volume":"121","author":"Li","year":"2023","journal-title":"Int immunopharmacol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1186\/s12906-025-05020-8","article-title":"Qingrehuoxue formula enhances anti-PD-1 immunotherapy in NSCLC by remodeling the tumor immune microenvironment via TREM2 signaling","volume":"25","author":"Li","year":"2025","journal-title":"BMC complement Med therapies"},{"key":"B19","article-title":"Lenvatinib promotes antitumor immunity by enhancing the tumor infiltration and activation of NK cells","volume":"9","author":"Zhang","year":"2019","journal-title":"Am J Cancer Res"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3779\/j.issn.1009-3419.2024.102.13","article-title":"Tumor-associated macrophage: Emerging targets for modulating the tumor microenvironment","volume":"27","author":"Zhou","year":"2024","journal-title":"Zhongguo fei ai za zhi = Chin J Lung cancer"},{"key":"B21","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/s41392-025-02193-z","article-title":"PD-1 antibody camrelizumab plus apatinib and SOX as first-line treatment in patients with AFP-producing gastric or gastro-esophageal junction adenocarcinoma (CAP 06): a multi-center, single-arm, phase 2 trial","volume":"10","author":"Wang","year":"2025","journal-title":"Signal transduct targeted Ther"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2015.02.011","article-title":"Clinical significance of assessing Her2\/neu expression in gastric cancer with dual tumor tissue paraffin blocks","volume":"46","author":"Ge","year":"2015","journal-title":"Hum pathol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v19.i14.2171","article-title":"Correlation of human epidermal growth factor receptor 2 expression with clinicopathological characteristics and prognosis in gastric cancer","volume":"19","author":"He","year":"2013","journal-title":"World J gastroenterol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3978\/j.issn.2095-6959.2019.09.026","article-title":"Research progress of HER2 heterogeneity in gastric cancer","volume":"39","author":"Wei","year":"2019","journal-title":"J Clin Pathol Res"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3978\/j.issn.1000-9604.2014.12.09","article-title":"HER2 discordance between paired primary gastric cancer and metastasis: a meta-analysis","volume":"27","author":"Peng","year":"2015","journal-title":"Chin J Cancer Res = Chung-kuo yen cheng yen chiu"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2023.11.001","article-title":"Targeting HER2 heterogeneity in breast and gastrointestinal cancers","volume":"10","author":"Valenza","year":"2024","journal-title":"Trends cancer"},{"key":"B27","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.ejca.2015.09.018","article-title":"Extra-gain of HER2-positive cases through HER2 reassessment in primary and metastatic sites in advanced gastric cancer with initially HER2-negative primary tumours: Results of GASTric cancer HER2 reassessment study 1 (GASTHER1)","volume":"53","author":"Park","year":"2016","journal-title":"Eur J Cancer (Oxford England: 1990)"},{"key":"B28","doi-asserted-by":"publisher","first-page":"199","DOI":"10.4143\/crt.2023.490","article-title":"GASTric cancer HER2 re-assessment study 2 (GASTHER2): HER2 re-assessment for initially HER2-negative advanced gastric cancer patients after progression on first-line treatment","volume":"56","author":"Hyung","year":"2024","journal-title":"Cancer Res Treat"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1002\/jbt.23446","article-title":"Cbl induced ubiquitination of HER2 mediate immune escape from HER2-targeted CAR-T","volume":"37","author":"Yang","year":"2023","journal-title":"J Biochem Mol toxicol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1007\/s00428-025-04057-x","article-title":"Clinicopathological characteristics and prognostic significance of HER2 status evaluation in patients with urothelial carcinoma: a retrospective single-center experience in China","volume":"26","author":"Yang","year":"2025","journal-title":"Virchows Archiv: an Int J pathol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.4081\/aiua.2023.11313","article-title":"HER2\/neu expression status of post BCG recurrent non-muscle-invasive bladder urothelial carcinomas in relation to their primary ones","volume":"95","author":"Ali","year":"2023","journal-title":"Archivio italiano di urologia andrologia: organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2021.1981284","article-title":"Combination of HER2-targeted agents with immune checkpoint inhibitors in the treatment of HER2-positive breast cancer","volume":"22","author":"Matusz-Fisher","year":"2022","journal-title":"Expert Opin Biol Ther"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1093\/jleuko\/qiaf107","article-title":"An IL-15-modified NKp30\u00d7HER2 trispecific NK cell engager enhances NK cell activation and tumor cell killing","volume":"117","author":"Cheng","year":"2025","journal-title":"J leukocyte Biol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3390\/life11090868","article-title":"Epigenetic silencing of HER2 expression during epithelial-mesenchymal transition leads to trastuzumab resistance in breast cancer","volume":"11","author":"Nami","year":"2021","journal-title":"Life (Basel Switzerland)"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2019.102612","article-title":"Contribution of synergism between PHF8 and HER2 signalling to breast cancer development and drug resistance","volume":"51","author":"Liu","year":"2020","journal-title":"EBioMedicine"},{"key":"B36","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1038\/s41419-020-03081-w","article-title":"The histone H2B ubiquitin ligase RNF40 is required for HER2-driven mammary tumorigenesis","volume":"11","author":"Wegwitz","year":"2020","journal-title":"Cell Death dis"},{"key":"B37","doi-asserted-by":"publisher","first-page":"8858","DOI":"10.1038\/s41598-020-65649-y","article-title":"Anesthetic propofol epigenetically regulates breast cancer trastuzumab resistance through IL-6\/miR-149-5p axis","volume":"10","author":"Tian","year":"2020","journal-title":"Sci Rep"},{"key":"B38","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1007\/s12032-025-02976-y","article-title":"The mechanism of ncRNA in trastuzumab resistance in HER2-positive tumors","volume":"42","author":"Zhao","year":"2025","journal-title":"Med Oncol (Northwood London England)"},{"key":"B39","doi-asserted-by":"publisher","first-page":"9928","DOI":"10.1038\/s41598-023-35925-8","article-title":"Genomic analysis of plasma circulating tumor DNA in patients with heavily pretreated HER2\u2009+\u2009metastatic breast cancer","volume":"13","author":"Lee","year":"2023","journal-title":"Sci Rep"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1696069\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T06:28:38Z","timestamp":1767335318000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1696069\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,2]]},"references-count":39,"alternative-id":["10.3389\/fimmu.2025.1696069"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1696069","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,2]]},"article-number":"1696069"}}